NuvaRing
Authors: Meghan Joslyn, Dana Erickson, Nicole Austreng, and Abbie Holig
NuvaRing is a birth control option that is administered monthly. When used as directed, it can be as effective as an oral contraceptive and more convenient as it does not need to be taken daily.
History
When Did Nuvaring Begin?
- October 3, 2001
- The FDA approved Nuvaring (4).
Who Founded the Product?
- Schering-Plough (Organon) company in the Netherlands founded Nuvaring (3).
Marketing
- 1st marketed in the USA in July 2002 (5).
Structure
- Chemical structure (3)
Etonogestrel & Ethinyl Estradiol
- Components: a progestin, etonogestrel and an estrogen, ethinyl estradiol
- The NuvaRing is a flexible ring about 2” in diameter that you insert vaginally once a month. Once inside, NuvaRing releases a continuous low dose of hormones to prevent pregnancy.
- What is the Nuvaring ring made of?
- NuvaRing is a nonbiodegradable, flexible, transparent, colorless to almost colorless, combination contraceptive vaginal ring containing two active hormones (6).
Function
How Nuvaring Effects Women & How it Works:
- NuvaRing is an estrogen/progestin birthcontrol ring that is inserted into the vagina once every four weeks. The ring is left in for three weeks and is taken out for menstruation. A new ring is inserted after the fourth week (6).
Insertion, Removal, & Complications:
A common question women ask about NuvaRing is “How exactly do you put it in?”
- NuvaRing is a small, flexible ring that is inserted very simply.
|
|
Why women use Nuvaring:
- Compared to other forms of birth control, NuvaRing is inserted once a month, provides low doses of estrogen and progestin, it is easy to use, doesn’t need to be fitted by a clinician, and is 99% effective (6).
Problems with Nuvaring
Possible side effects of NuvaRing include:
- vaginal infections, irritation, and secretion
- headaches
- weight gain
- nausea
Side effects noted when NuvaRing is used as a hormonal birth control method:
Graph 1. Data from study "Cycle Control, Tolerability, Efficacy, and Acceptability of the Vaginal Contraceptive Ring, NuvaRing; Results of Clinical Experience in Germany" (1).
Side effects also place NuvaRing users at a risk for:
- heart attacks
- blood clots
- gallbladder disease
- breast cancer
- reproductive organ cancer
- high blood pressure
- liver tumors
- defects of lipid metabolism (cause inflammation of the pancreas)
Current Problems
- Women should discuss NuvaRing with their doctor before using it if they have any of the following conditions (2):
- Circulation Problems
- Gallbladder, Heart, Kidney, or Liver Disease
- Migraines
- High Blood Pressure
- Breast Cancer
- Heavy Smoker
- Vaginal Bleeding
- Pregnant (may be pregnant)
- Have not yet menstruated
- During a study called "Cycle Control, Tolerability, Efficacy, and Acceptability of the Vaginal Contraceptive Ring, NuvaRing; Results of Clinical Experience in Germany," 5823 women were surveyed and their reponses are displayed in the graph below (1).
Graph 2. Response Classifications: Satisfaction with NuvaRing, Continued Use of NuvaRing, and Recommendation of NuvaRing to Others.
NuvaRing is a monthly form of birth control that is 99% effective when used correctly. There are many forms of birth control available today, however the NuvaRing is a slightly different option that delivers hormones directly into the vagina.
Information Sources:
(1) "Cycle Control, Tolerability, Efficacy, and Acceptability of the Vaginal Contraceptive Ring, NuvaRing; Results of Clinical Experience in Germany." European Journal of Contraception & Reproductive Health Care, March 2008. Vol. 13 Issue 1, p31-38.
(2) "Ethinyl Estradiol and Etonogestrel." Lex-PALS Drug Guide, Nov 2009. p1-1.
(3) Faundes, A. "Pros and cons of vaginal rings for contraceptive hormone delivery." American Journal of Drug Delivery, 2004, 2 (4): 241-50.
(4) "Human Pharmaceutical." Schering-Plough, Schering-Plough Corporation, 2009. Web. 21 Oct 2009. <http://www.schering-plough.com/products/human-prescription.aspx#1>.
(5) "NME Drug and New Biologic Approvals in 2001." FDA U.S Food and Drug Administration, U.S. Department of Health & Human Services. Web. 21 Oct. 2009. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelope
dandApproved/DrugandBiologicApprovalReports/NMEDrugandNewBiologicApprovals
/ucm081684.htm> .
(6) "Nuvaring." Nuvaring. Organon Oss: The Netherlands. Web. 21 Oct. 2009. <http://www.nuvaring.com/Consumer/index.asp>.
**All hand-drawn pictures were done by Meghan Joslyn.